Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
The Ma’anshan site approval covers pastilles, oral liquids, and powders
Mansam, founded in 2022, is positioned as the first Arabian luxury fragrance brand with a vision for global expansion
New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
The cGMP-4 facility will further strengthen the company's ability to serve global partners
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Funding to support Phase 2b trial with MRM Health’s lead program MH002 in ulcerative colitis and advance two additional programs to IND approval
Subscribe To Our Newsletter & Stay Updated
